| Name | GSK3145095 |
|---|---|
| Synonyms |
GSK3145095, 10 mM in DMSO
1H-1,2,4-Triazole-5-cboxamide, N-[(3S)-7,9-difluoro-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazin-3-yl]-3-(phenylmethyl) Inhibitor,GSK3145095,inhibit,RIP kinase,GSK-3145095,Rector-interacting protein kinases,RIPK,GSK (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azin-3-yl)-4H-1,2,4-triazole-3-cboxamide |
| Description | GSK3145095 is a RIP1 kinase inhibitor with an IC50 of 6.3 nM [1]. |
|---|---|
| Related Catalog | |
| Target |
IC50: 6.3 nM (RIP1 kinase )[1] |
| In Vitro | GSK3145095 potently blocks the TNF response as shown by determination of overall cell viability as measured by cellular ATP levels (IC50 = 1.6 nM), cell death as measured by LDH release (IC50 = 0.5 nM) and RIP1-dependent inflammatory cytokine MIP-1β production, either as absolute levels for protein, or fold changes in mRNA expression (IC50 = 0.4 nM) [1]. |
| References |
| Molecular Formula | C20H17F2N5O2 |
|---|---|
| Molecular Weight | 397.38 |